Samsara BioCapital, LLC 13F: Quarter-over-Quarter Portfolio Changes
Samsara BioCapital, LLC reported a disclosed portfolio value of approximately $1.0 billion in its latest SEC Form 13F-HR filing for Q1 2026, up 6.2% quarter on quarter. Over the quarter, the fund initiated 3 new positions, bought more shares in 2 holdings, trimmed 3 holdings, and exited 2 positions.
Samsara BioCapital, LLC's top buy was a new stake in Spyglass Pharma INC (SGP) , equal to 5.3% of the disclosed portfolio. Its top sell was Palvella Therapeutics INC Ne (PVLA) . The fund sold 63.3% of its previously reported shares, reducing the position's portfolio weight by 0.7 percentage points.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| SPYGLASS PHARMA INC | SGP | 5.3% | History → |
| AGOMAB THERAPEUTICS NV | AGMB | 0.6% | Holders → |
| COHERUS ONCOLOGY INC | CHRS | 0.6% | Holders → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| SUTRO BIOPHARMA INC | STRO | +2.3% | +419.7% | History → |
| ALUMIS INC | ALMS | +7.8% | +10.2% | History → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| PALVELLA THERAPEUTICS INC NE | PVLA | -0.7% | 63.3% | Holders → |
| ABIVAX SA | ABVX | -0.4% | 25.0% | Holders → |
| X4 PHARMACEUTICALS INC | XFOR | -0.1% | 6.5% | Holders → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CONTINEUM THERAPEUTICS, INC. | CTNM | 0.1% |
| NUVATION BIO INC | NUVB/WS | 0.0% |
Net Portfolio Value ChangeQ1 2026
- $1.0BPrior quarter
- $1.0BCurrent quarter
- +$0.1BNet delta
- +6.2%% change
Methodology & FAQ
How Samsara BioCapital, LLC Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Samsara BioCapital, LLC: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Samsara BioCapital, LLC buy in Q1 2026?
In Q1 2026, Samsara BioCapital, LLC initiated 3 new positions (SPYGLASS PHARMA INC (SGP), AGOMAB THERAPEUTICS NV (AGMB), COHERUS ONCOLOGY INC (CHRS)); bought more shares of SUTRO BIOPHARMA INC (STRO), ALUMIS INC (ALMS).
What stocks did Samsara BioCapital, LLC sell in Q1 2026?
In Q1 2026, Samsara BioCapital, LLC fully sold 2 positions (CONTINEUM THERAPEUTICS, INC. (CTNM), NUVATION BIO INC (NUVB/WS)); reduced holdings in PALVELLA THERAPEUTICS INC NE (PVLA), ABIVAX SA (ABVX), X4 PHARMACEUTICALS INC (XFOR).
Which positions did Samsara BioCapital, LLC initiate in Q1 2026?
Samsara BioCapital, LLC established 3 new positions in Q1 2026: SPYGLASS PHARMA INC (SGP, 5.3%), AGOMAB THERAPEUTICS NV (AGMB, 0.6%), COHERUS ONCOLOGY INC (CHRS, 0.6%).
Which existing positions saw the largest allocation increases for Samsara BioCapital, LLC in Q1 2026?
Of 2 existing positions with share-count increases in Q1 2026, the largest were: SUTRO BIOPHARMA INC (STRO, +2.3% weight, +419.7% shares), ALUMIS INC (ALMS, +7.8% weight, +10.2% shares).
Which positions did Samsara BioCapital, LLC fully exit in Q1 2026?
Samsara BioCapital, LLC fully exited 2 positions in Q1 2026: CONTINEUM THERAPEUTICS, INC. (CTNM, last-reported weight 0.1%), NUVATION BIO INC (NUVB/WS, last-reported weight 0.0%).
Which existing positions saw the largest allocation reductions for Samsara BioCapital, LLC in Q1 2026?
Of 3 existing positions with share-count reductions in Q1 2026, the largest were: PALVELLA THERAPEUTICS INC NE (PVLA, -0.7% weight, -63.3% shares), ABIVAX SA (ABVX, -0.4% weight, -25.0% shares), X4 PHARMACEUTICALS INC (XFOR, -0.1% weight, -6.5% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.